洛铂联合紫杉醇在食管癌新辅助化疗中的应用

Application of neoadjuvant chemotherapy with lobaplatin plus paclitaxel in treating esophageal carcinoma

目的评价洛铂联合紫杉醇在局部进展期食管癌新辅助治疗中的疗效和安全性。方法选取2016年1月~2017年12月在我院行新辅助化疗患者264例,均为局部进展期食管鳞状细胞癌。按自愿原则分入TL组(洛铂联合紫杉醇)63例,TP组(顺铂联合紫杉醇)201例。对比两组患者的近期疗效及不良反应。结果两组患者均完成2个周期的新辅助化疗,无治疗相关性死亡。TL组CR 3例,PR36例,SD20例,PD4例,ORR为61.9%,DCR为93.7%;TP组CR19例,PR 106例,SD68例,PD 8例,ORR为62.2%,DCR为96.0%。TL组与TP组比较,客观缓解率无统计学差异(P>0.05)。但TL组患者血小板减少、恶心/呕吐毒副作用发生例数显著少于对照组,差异具有统计学意义(P<0.05)。结论洛铂用于局部进展期食管癌新辅助治疗与顺铂疗效相当,但安全性优于顺铂,是临床可选治疗方案。

Objective To investigate the efficacy and toxicity of neoadjuvant chemotherapy with paclitaxel plus lobaplatin in locally advanced esophageal squamous cell carcinoma(ESCG).Methods Selected 264 patients with locally advanced esophageal squamous cell carcinoma from Jan 2016 to Dec 2017 in our hospital.On the basis of the principle of voluntary participation,patients were divided into TL group(lobaplatin plus paclitaxel,n二63)and TP group(cisplatin plus paclitaxel).Curative effect and toxicity rates between the two groups were compared.Results Two cycles of neoadjuvant chemotherapy were completed in the two groups and there was no treatment related death.ORR and DCR were 61.9%and 93.7%in TL group.ORR and DCR were 62.2%and 96.0%in TP group.There was no significant difference in the ORR between two groups(P>0.05).The incidence of thrombocytopenia nausea/vomiting in TL group were significantly lower than TP group,the differences were statistically significant(P<0.05).Conclusion Lobaplatin/cispaltin combined with paclitaxel for preoperative neoadjuvant chemotherapy have similar efficacy in the treatment of locally advanced ESCG,and lobaplatin has better safety,which is one of clinical treatment options.